Pharmaceutical Companies Eye India
On May 21, Abbott Laboratories announced that it would purchase Piramal Healthcare, a branded generics company based in India, for $3.72 billion.
daiichi sankyo
AstraZeneca’s Heart Drug Beats Plavix in Phase III Study
Blood-thinning drug Plavix racks up over $8 billion in annual sales, but the blockbuster medication may have some new competition.